<DOC>
	<DOCNO>NCT01036594</DOCNO>
	<brief_summary>This open label , phase II , single center trial ketoconazole/dexamethasone determine administration ketoconazole/dexamethasone , disease progression ketoconazole/hydrocortisone slow reverse disease progression men progressive prostate cancer .</brief_summary>
	<brief_title>Ketoconazole Dexamethasone Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate . Testosterone &lt; 50 ng/dL . Patients must continue primary androgen deprivation LHRH analogue undergone orchiectomy . Progressive nonmetastatic metastatic disease androgen deprivation . Patients must EITHER : 1 . Progression define RECIST criterion . OR 2 . Progressive PSA document within 4 week enrollment . PSA evidence progressive prostate cancer consist PSA level least 5 ng/ml rise least 2 successive occasion , least 2 week apart . If confirmatory PSA value less first document rise PSA value , additional test rise PSA required document progression . Patients receive antiandrogen part primary androgen ablation must demonstrate disease progression follow discontinuation antiandrogen . 1 . Disease progression antiandrogen withdrawal define 2 consecutive rise PSA value , obtain least 2 week apart , document osseous soft tissue progression . 2 . For patient receive flutamide , least one PSA value must obtain 4 week flutamide discontinuation . 3 . For patient receive bicalutamide ( Casodex ) nilutamide , least one PSA value must obtain 6 week antiandrogen discontinuation . Karnofsky Performance Status ≥ 60 % . Patients receive hormonal therapy , include dose megestrol acetate ( Megace ) , Proscar ( finasteride ) , herbal product know decrease PSA level ( e.g. , Saw Palmetto PCSPES ) , systemic corticosteroid must discontinue agent least 4 week prior enrollment . Patients stable dos bisphosphonates may continue medication ; , patient may initiate bisphosphonate therapy time ketoconazole initiation . Prior radiation therapy complete ≥ 4 week prior enrollment . Liver function test ( ALT , AST , Bilirubin ) must within normal limit . ANC &gt; 1500/µl , Platelet count &gt; 100,00/µl , Creatinine &lt; 1.5 x upper limit normal ( ULN ) , Hemoglobin &gt; 8 mg/dl . Prior chemotherapy prostate cancer allow exception case chemotherapy administer neoadjuvant adjuvant fashion AND &gt; 1 year elapse since administration therapy . No prior ketoconazole , abiraterone , aminoglutethimide corticosteroid treatment progressive prostate cancer . No supplement complementary medicines/botanicals permit protocol therapy , except combination following : ( conventional multivitamin supplement , selenium , lycopene , soy supplement ) No prior radiopharmaceutical ( strontium , samarium ) within 8 week prior enrollment . No `` currently active '' second malignancy , nonmelanoma skin cancer . No serious intercurrent infection nonmalignant medical illness uncontrolled . No psychiatric illnesses/social situation would limit compliance No active uncontrolled autoimmune disease . No adrenal insufficiency demonstrate baseline ACTH stimulation test demonstrate peak cortisol &gt; 18 µg/dL .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ketoconazole</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>